Trials / Recruiting
RecruitingNCT05434598
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ChromoSeq | Novel, streamlined whole genome sequencing approach |
Timeline
- Start date
- 2022-07-27
- Primary completion
- 2027-07-31
- Completion
- 2027-08-31
- First posted
- 2022-06-28
- Last updated
- 2025-12-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05434598. Inclusion in this directory is not an endorsement.